Table 3.
Clinical Features of ER-Positive ESR1-Mutant Metastatic Patients (N=8)
| Patients | DNA Alteration Code and Alteration Frequency | Amino Changes | HER2 Status | Pathologic Type and Grade | Metastasized Organs | Endocrine Therapy Drugs | AIs Therapy Time (Month) |
|---|---|---|---|---|---|---|---|
| Case 1 | 1138G>C 2.72% 1609T>A 0.69% |
E380Q Y537N |
Positive | Invasive ductal carcinoma, grade II | Bone, lung, liver, soft tissues | Letrozole | 25 |
| Case 2 | 1613A>G 2.74% 1265_1267del 0.47% |
D538G V422del |
Negative | Invasive ductal carcinoma, grade III | Bone | Exemestane | 28 |
| Case 3 | 1610A>C 2.07% | Y537S | Negative | Invasive micro-papillary carcinoma, grade unknown | Lung | Anastrozole | 18 |
| Case 4 | 1610A>C 1.09% | Y537S | Negative | Invasive mucinous carcinoma, grade I | Bone, lung, liver | Letrozole | 22 |
| Case 5 | 1138G>C 4.26% | E380Q | Negative | Invasive ductal carcinoma, grade II | Liver | Anastrozole | 16 |
| Case 6 | 1613A>G 2.83% | D538G | Negative | Invasive ductal carcinoma, grade III | Bone, lung, liver | Exemestane | 48 |
| Case 7 | 1607_1608delinsAT 9.3% | L536H | Negative | Invasive ductal carcinoma, grade III | Chest wall | Letrozole | 29 |
| Case 8 | 1613A>G 6.6% | D538G | Negative | Invasive ductal carcinoma, grade III | Lung, liver, soft tissue | Tamoxifen anastrozole |
16 |